



SAVING LIVES,  
ONE HEART AT A TIME

## Job Description

# Position

Position:

**Xxx**

Reports to:

**Xxx**

Reports to:

**Tucson, AZ**

### Company description:

SynCardia Systems, LLC, a Picard Medical Company, is headquartered in Tucson, AZ. We manufacture and sell the world's first and only US Food and Drug Administration (FDA) and Health Canada approved total artificial heart as bridge to transplant for patients suffering from biventricular heart failure. The SynCardia Total Artificial Heart™ is available in two sizes to accommodate patients' diverse physiologies. The Freedom Portable Driver™ allows clinically stable patients to be discharged from the hospital to enjoy life at home while they wait for a heart transplant. The SynCardia Total Artificial Heart™ has been successfully used in over 2,000 patients and is the most widely used and extensively studied total artificial heart in the world. For additional information and label information, visit us at [www.syncardia.com](http://www.syncardia.com).

### Position description:

Text

### Principal responsibilities:

- Bullets

## Job Description

# Position

### Requirements:

- Bullets

### Qualifications:

- Bullets

### Application process:

Text



#### SynCardia Systems, LLC

1992 E. Silverlake Rd. Tucson, AZ 85713 | US

+1 520-545-1234 | [info@syncardia.com](mailto:info@syncardia.com)

[www.Syncardia.com](http://www.Syncardia.com)



#SynCardia

#### About SynCardia Systems, LLC

SynCardia Systems, LLC, a Picard Medical Company, is headquartered in Tucson, AZ. We manufacture and distribute the world's first and only US Food and Drug Administration (FDA) and Health Canada approved total artificial heart. The SynCardia Total Artificial Heart is the most widely used and extensively studied artificial heart in the world.

#### The SynCardia Total Artificial Heart (STAH)

The STAH has been successfully implanted in over 2,000 patients suffering from advanced stage heart failure. The implant is available in two sizes to accommodate patients' diverse physiologies. The STAH is approved for sale in the US and in Canada where it is indicated for use in cardiac transplant-eligible patients at risk of imminent death from biventricular failure. EU and international approvals are pending. For additional information and label information, visit us at [www.syncardia.com](http://www.syncardia.com).

#### About Heart Failure\*

Heart failure (HF) is a growing burden for the United States and other developed countries due to the aging of their populations. Approximately 6.7 million individuals had HF in 2023 and the prevalence of advanced stage HF has been estimated to be as high as 25% of the total HF populations. Approximately 300,000 (5%) of advanced stage HF are refractory to guideline directed therapy.

#### Medical Advice Disclaimer

The information, including but not limited to, text, graphics, images, and other components contained in this material are for informational purposes only. No information in this material is intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or a qualified health care provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of information you have read in this material.

\* Bozkurt B, et al., J Card Fail. 2023 Oct;29(10):1412-1451; (2) Abouezzeddine et al., Congest Heart Fail. 2011 Jul-Aug;17(4):160-8.